Newswire (Published: Monday, May 18, 2020, Received: Monday, May 18, 2020, 3:51:52 PM CDT)

Word Count: 552

2020 MAY 18 (NewsRx) -- By a News Reporter-Staff News Editor at Genomics & Genetics Daily -- Fresh data on Oncology - Prostate Cancer are presented in a new report. According to news reporting originating from Durham, North Carolina, by NewsRx correspondents, research stated, “The impact of race on prostate cancer skeletal-related events (SREs) remains understudied. In the current study, the authors tested the impact of race on time to SREs and overall survival in men with newly diagnosed, bone metastatic castration-resistant prostate cancer (mCRPC).”

Our news editors obtained a quote from the research from the Duke University School of Medicine, “The authors performed a retrospective study of patients from 8 Veterans Affairs hospitals who were newly diagnosed with bone mCRPC in the year 2000 or later. SREs comprised pathologic fracture, spinal cord compression, radiotherapy to the bone, or surgery to the bone. Time from diagnosis of bone mCRPC to SREs and overall mortality was estimated using the Kaplan-Meier method. Cox models tested the association between race and SREs and overall mortality. Of 837 patients with bone mCRPC, 232 patients (28%) were black and 605 (72%) were nonblack. At the time of diagnosis of bone mCRPC, black men were found to be more likely to have more bone metastases compared with nonblack men (29% vs 19% with 10 bone metastases; p=.021) and to have higher prostate-specific antigen (41.7 ng/mL vs 29.2 ng/mL; p=.005) and a longer time from the diagnosis of CRPC to metastasis (17.9 months vs 14.3 months; p<.01). On multivariable analysis, there were no differences noted with regard to SRE risk (hazard ratio [HR], 0.80; 95% CI, 0.59-1.07) or overall mortality (HR, 0.87; 95% CI, 0.73-1.04) between black and nonblack people, although the HRs were <1, which suggested the possibility of better outcomes. No significant association between black race and risk of SREs and overall mortality was observed in the current study.”

According to the news editors, the research concluded: “These data have suggested that efforts to understand the basis for the excess risk of aggressive prostate cancer in black men should focus on cancer development and progression in individuals with early-stage disease.”

For more information on this research see: Race does not predict skeletal-related events and all-cause mortality in men with castration-resistant prostate cancer. Cancer, 2020;():. Cancer can be contacted at: John Wiley & Sons Inc, 111 River St, Hoboken, NJ 07030, USA. (Wiley-Blackwell -; Cancer -

The news editors report that additional information may be obtained by contacting L.E. Howard, Duke Cancer Institute, Duke University School of Medicine, Durham, North Carolina, United States. Additional authors for this research include D.N. Patel, A.M. De Hoedt, C.L. Amling, W.J. Aronson, M.R. Cooperberg, C.J. Kane, Z.W. Klaassen, M.K. Terris and S.J Freedland.

The direct object identifier (DOI) for that additional information is: This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

Publisher contact information for the journal Cancer is: John Wiley & Sons Inc, 111 River St, Hoboken, NJ 07030, USA.

(Our reports deliver fact-based news of research and discoveries from around the world.)


John Wiley & Sons Inc.


North America
United States
North Carolina
New Jersey


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer